Arcus Biosciences, Inc.
RCUS- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001724521
In the last 90 days, Arcus Biosciences, Inc. insiders filed 0 open-market purchases and 2 sales; 231 institutions reported holding it in 13F filings for Q2 2026, worth $3.78B in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Arcus Biosciences, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 173 | 183 | +10 |
| Shares | 52.4M | 52.5M | +25.8K (0.0%) |
| Value | $1.33B | $1.37B | +$43.6M (+3.3%) |
New holders (26)
Institutions that held Arcus Biosciences, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
Sold out (16)
Institutions that held Arcus Biosciences, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Balyasny Asset Management LLC | 408,122 | $10.3M |
| Acuta Capital Partners, LLC | 167,500 | $4.24M |
| Bain Capital Public Equity Management II, LLC | 148,887 | $3.77M |
| Capital Fund Management S.A. | 96,224 | $2.44M |
| Quantedge Capital Pte Ltd | 39,600 | $1.00M |
| SG Americas Securities, LLC | 37,557 | $952.0K |
| HRT Financial LP | 34,674 | $878.0K |
| Bayesian Capital Management, LP | 13,736 | $348.0K |
| Guggenheim Capital LLC | 9,903 | $251.0K |
| Gsa Capital Partners LLP | 9,888 | $251.0K |
| Trexquant Investment LP | 8,190 | $208.0K |
| Janus Henderson Group PLC | 8,096 | $205.0K |
| Captrust Financial Advisors | 2,072 | $53.0K |
| State of Wyoming | 1,611 | $41.0K |
| Lindbrook Capital, LLC | 59 | $1.00K |
| Steward Financial Group LLC | 13 | $0 |